Adlai Nortye (NASDAQ:ANL) Trading Down 5.5% – Here’s What Happened

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL)’s share price was down 5.5% during trading on Thursday . The company traded as low as $1.55 and last traded at $1.55. Approximately 1,683 shares were traded during trading, a decline of 86% from the average daily volume of 12,207 shares. The stock had previously closed at $1.64.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut Adlai Nortye from a “buy” rating to a “neutral” rating in a research report on Monday, June 2nd.

Adlai Nortye Trading Down 5.5%

The stock’s fifty day moving average is $1.78 and its two-hundred day moving average is $2.03. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.02.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.